The present invention relates to the use of oligomeric siloxane components in radiation-curable formulations which in the cured state offer a particular degree of corrosion control for metallic substrates.
Radiation-curable formulations are known.
Ethylenically unsaturated prepolymers are described in, for example, P. K. T. Oldring (ed.), “Chemistry and Technology of UV and EB Formulations for Coatings, Inks and Paints”, vol. II., SITA Technology, London 1991, based for example on epoxy acrylates (pages 31 to 68), urethane acrylates (pages 73 to 123) and melamine acrylates (pages 208 to 214). Formulations of this kind are frequently mentioned in the patent literature as well: examples include JP 62110779 and EP 947 565.
The coating of metallic substrates poses a particular problem for radiation-curable formulations, since processes of contraction may result in loss of adhesion. For such substrates it is therefore common to use adhesion promoters containing phosphoric acid. Examples of this are U.S. Pat. No. 5,128,387 (coating of beer cans) and JP 2001172554 (coating of various cans).
Epoxy acrylates are known to exhibit outstanding adhesion and effective corrosion control on metal substrates. A disadvantage of such coatings, however, is the low level of deformability after curing. For certain coating technologies, coil coating being one example, the deformability of the coated workpieces without the coating cracking is critical. Moreover, on account of their aromatic fractions, coatings of this kind have a tendency towards yellowing.
WO 03/022945 describes low-viscosity radiation-curable formulations for metal substrates that are based on radiation-curable resins, monofunctional reactive diluents, and acidic adhesion promoters. The resins employed are typical commercial products available from a variety of suppliers.
EP 902 040 as well relates to radiation-curable formulations. Described therein are urethane (meth)acrylates with monofunctional esters of an unsaturated carboxylic acid, which are esterified with alcohols containing a carbocyclic or heterocyclic ring.
The systems known from the prior art, however, in many cases exhibit disadvantages; more particularly, the deformability and the stability do not always meet the requirements that are imposed.
An object of the present invention is to find radiation-curable formulations which on the one hand are readily deformable, i.e. flexible, after coating, but on the other hand also ensure outstanding corrosion control for metal substrates.
Surprisingly it has been found that the corrosion resistance of coating materials based on radiation-curable formulations on metallic substrates increases if oligomeric siloxane components are included in the formulation. Radiation-curable formulations for the purposes of the present invention are formulations which can be cured by IR or UV radiation, electron beams, microwave radiation, laser beams or plasma.
Accordingly the present invention first provides for the use of oligomeric siloxane components in radiation-curable formulations, more particularly coating materials. Particularly suitable are hydrolysed and condensed organosilanes which are obtainable by controlled hydrolysis and condensation of at least one epoxy-functional silane of the general formula I
R1—SiR′m(OR)3-m (I),
in which R1 is a group
and the groups R, R′ and R″ are alike or different and in each case are a hydrogen (H) or are a linear, branched or cyclic, unsubstituted or substituted alkyl group having 1 to 6 C atoms, preferably H, methyl, ethyl, n-propyl, n-butyl, groups A and A′ are alike or different and in each case are a divalent alkyl group having 1 to 10 C atoms, preferably —(CH2)2—, —(CH2)2—, —(CH2)3—, —(CH2)(CH)(CH3)(CH2)— for A′ and also —(CH2)— for A, and m is 0 or 1, in the presence of boric acid [H3BO3 or B(OH)3].
Likewise provided by the present invention are radiation-curable formulations comprising at least one radiation-curable resin and at least 2% by weight of at least one oligomeric siloxane component, based on the total formulation. A preferred radiation-curable formulation in accordance with the present invention is more particularly the formulation composed of
The radiation-curable formulations of the invention have the advantage that, on application, improved flexibility and effective corrosion control are achieved.
One important constituent of the formulations of the invention are the radiation-curable resins A). These are systems that are known to a person skilled in the art. The preparation of radiation-curable resins, oligomers and/or polymers, is described in, for example, “Radiation Curing in Polymer Science & Technology, Vol. I: Fundamentals and Methods” by J. P. Fouassier, J. F. Rabek, Elsevier Applied Science, London and New York, 1993, chapter 5, pages 226 to 236, in “Lackharze” [Resins for Coatings], D. Stoye, W. Freitag, Hanser-Verlag, Vienna, 1996, pages 85, 94-98, 169 and 265, and in EP 947 565.
For the resins A) a distinction according to raw materials basis is made between, for example, epoxy acrylates, polyester acrylates, polyether acrylates, polyacrylate acrylates, and urethane acrylates, alone or in a mixture. The latter may be based, for example, on polyesters or else on polyethers. The corresponding methacrylates are known as well. Other polymerizable groups are epoxides and vinyl ethers. These too may be attached to different base resins.
The amount of A) in the formulation varies from 5% to 95% by weight, preferably 10% to 39% by weight. Particular preference is given to polyesterurethane acrylates. Examples thereof are VESTICOAT EP 110 IBOA (commercial product of Degussa GmbH, Germany, Coatings & Colorants, difunctional polyesterurethane acrylate) and EBECRYL 1256 (commercial product of Cytec).
A further important constituent of the formulations of the invention are the oligomeric siloxane components B). The fraction of oligomeric siloxane components B) as a proportion of the total formulation is more particularly 2% to 25% by weight, preferably 5% to 15% by weight. One process, which is general knowledge, for the preparation of hydrolysed organosilanes B) of this kind is the sol-gel process, as described comprehensively by C. J. Brinker and G. W. Scherer in Sol-Gel Science: The Physics and Chemistry of Sol-Gel Processing, Academic Press, New York (1990).
More particularly preferred are the oligomeric siloxane components obtainable by controlled hydrolysis and condensation of at least one epoxy-functional silane of the general formula I
R1—SiR′m(OR)3-m (I),
in which R1 is a group
and the groups R, R′ and R″ are alike or different and in each case are a hydrogen (H) or are a linear, branched or cyclic, unsubstituted or substituted alkyl group having 1 to 6 C atoms, preferably H, methyl, ethyl, n-propyl, n-butyl, groups A and A′ are alike or different and in each case are a divalent alkyl group having 1 to 10 C atoms, preferably —(CH2)2—, —(CH2)2—, —(CH2)3—, —(CH2)(CH)(CH3)(CH2)— for A′ and also —(CH2)— for A, and m is 0 or 1, in the presence of boric acid.
Typically the preparation of sol-gel systems uses the water usually in an excess. The objective here is to maximise the degree of hydrolysis. Many silanes, unfortunately, do not undergo full hydrolysis under these conditions. For example, in the hydrolysis of the 3-glycidyloxypropyltrimethoxysilane, there remains a monomer fraction of approximately 90% (area percent GC TCD) even with a high concentration of acidic catalysts, such as HCl or acetic acid, even after hours, and even after hydrolysis at elevated temperature.
For this purpose, in a parallel application, a new method has been provided that allows epoxy-functional silanes, more particularly 3-glycidyloxypropylalkoxy-silanes per se or corresponding mixtures of organoalkoxysilanes containing 3-glycidyloxypropyl-alkoxysilane, to be hydrolysed, and at least proportionally condensed, with a substoichiometric amount of water, reliably and to a very high degree, using boric acid.
During the curing of the coating, the siloxane oligomer that is used co-crosslinks with, for example, an organic polyesterurethane acrylate and is able through further functional groups to make a contribution to improved substrate adhesion.
During the hydrolysis and condensation it is additionally possible to have at least one further organofunctional silane present, of the general formula II
R2—SiR′n(OR)3-n (II)
in which R2 is a linear, branched or cyclic, unsubstituted or substituted alkyl group having 1 to 20 C atoms, substituted for example by N—, O—, S— or halogen-bearing groups, such as fluoroalkyl, amino-alkyl, mercaptoalkyl, methacryloyloxyalkyl or OR, i.e. OH or alkoxy, more particularly methoxy or ethoxy, R′ is methyl, groups R independently are a hydrogen or are a linear, branched or cyclic alkyl group having 1 to 6 C atoms, and n is 0 or 1. In accordance with formula II it is possible with advantage in the process of the invention to use methoxysilanes or ethoxysilanes which carry more particularly a functional group R2 from the series, methoxy, ethoxy, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-octyl, isooctyl, tridecafluoro-1,1,2,2-tetrahydrooctyl, to name but a few examples—by way of example, but not exclusively, methyltrimethoxysilane, methyltriethoxysilane, vinyl-trimethoxysilane, vinyltriethoxysilane, n-propyl-trimethoxysilane, n-propyltriethoxysilane, n-octyl-trimethoxysilane, n-octyltriethoxysilane, hexadecyl-trimethoxysilane, hexadecyltriethoxysilane, tridecafluoro-1,1,2,2-tetrahydrooctyltrimethoxysilane, tridecafluoro-1,1,2,2-tetrahydrooctyltriethoxysilane, methacryloyloxypropyltrimethoxysilane, methacryloyloxy-propyltriethoxysilane, mercaptopropyltrimethoxysilane, mercaptopropyltriethoxysilane, tetramethoxysilane, tetraethoxysilane.
In the preparation of the siloxane component 0.001 to ≦5 mol of water is used per mole of alkoxy function in the silanes used; besides boric acid as a hydrolysis catalyst and the condensation component, no further hydrolysis catalyst or condensation catalyst is used and the condensates formed in the reaction are based on Si—O—B and/or Si—O—Si bonds.
In the reaction, per mole of alkoxy function of formula I and/or II that is used, it is preferred to use 0.05 to 5 mol, more preferably 0.1 to 2 mol, very preferably 0.15 to 1 mol, more particularly all numerical values in-between, between 0.15 to 1 mol—for example, but not exclusively, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 mol of water.
Preference is further given in the process, per mole of silane that is used, to 0.001 to 1 mol of boron, more preferably 0.01 to 0.5 mol, more particularly 0.07 to 0.76 mol of boron, which is introduced advantageously in the form of boric acid [H3BO2 or B(OH)3].
In the process, moreover, the reaction is carried out advantageously at a temperature in the range from 0 to 200° C., preferably at 40 to 150° C., more preferably from 50 to 100° C., very preferably 60 to 80° C.
Hence the reaction is carried out, more particularly with thorough mixing, over 0.1 to 100 h, preferably 0.5 to 20 h, more preferably 1 to 10 h, very preferably over 2 to 6 h.
It is likewise possible and advantageous, in the case of the stated process, to remove at least a proportion of the alcohol and/or boric ester present from the resulting product mixture, in a conventional distillation under reduced pressure. Alternatively such constituents can be removed from the product by means of short-path evaporators and/or thin-film evaporators. Furthermore, products obtained in this way can—if necessary—be filtered or centrifuged in order to separate off suspended particles. This can be done using, for example, a filter or a centrifuge.
With more particular preference the glycidylpropyl-alkoxysilane of the general formula I is glycidyloxypropyltrimethoxysilane or glycidyloxypropyltriethoxysilane.
By way of example it is possible advantageously to carry out a virtually complete hydrolysis of 3-glycidyloxypropyltrimethoxysilane (GLYMO) with an amount of water of 0.05 to 5, preferably 0.1 to 2, more particularly 0.15 to 1 mol of water per mole of alkoxy function used, with the use or in the presence of boric acid. More particularly it is possible over the course of just 7 hours to react as good as all of the GLYMO to oligomeric products by means of boric acid catalysis. A virtually complete hydrolysis in this context means that less than 20% by weight or area % (GC-TCD %) of the monomeric silane originally used remains unhydrolysed in the reaction space after the hydrolysis has been performed.
Reaction checking (determination of the concentration of monomeric silanes in the reaction mixture) is accomplished preferably by way of standard gas chromatography (HP 5890 series II, thermal conductivity detector). Temperature measurement may be accomplished conventionally via thermocouples. Pressure measurement is accomplished, for example, by means of piezoelectric pressure transducers (e.g. Vacubrand DVR 2). The residual monomer content of the products can be checked additionally via 29Si NMR spectroscopy, and is situated advantageously in the range from 5 to 17 mol %. The degree of crosslinking of the product was ascertained by determining the M, D and T structural units via 29Si NMR spectroscopy. In the silane condensates of the invention the fraction of M structural units is preferably in the range from 14 to 35 mol %, that of D structures in the range from 36 to 42 mol %, and that of T structures in the range from 15% to 34%. The hydro-methanolysis of the epoxide group can be determined via 13C NMR spectroscopy. Advantageously the product compositions of the invention contain only a fraction of 3 to 7 mol % of opened epoxide, based on the epoxide fraction originally used.
Optionally the formulations of the invention may contain adhesion promoters C). Adhesion promoters for radiation-curable formulations for metallic substrates are generally composed of phosphoric acid and/or phosphonic acid and/or reaction products thereof (e.g. esters) with functionalized acrylates. While the free phosphoric acid groups are responsible for the direct adhesion to the metal, the acrylate groups ensure a bond with the coating matrix. Products of this kind are described in, for example, WO 01/98413, JP 08231564, and JP 06313127, whose disclosure content is hereby incorporated by reference.
Typical commercial products are EBECRYL 169 and 170 from Cytec, ALDITOL Vxl 6219 from VIANOVA, CD 9050 and CD 9052 from Sartomer, SIPOMER PAM-100, SIPOMER PAM-200 and SIPOMER PAM-300 from Rhodia, and GENORAD 40 from Rahn. The amount of C) in the formulation is 0.1% to 10% by weight, preferably from 1% to 5% by weight.
The formulations of the invention may likewise include radiation-curable reactive diluents D). Radiation-curable reactive diluents D) and their preparation are described in, for example, “Radiation Curing in Polymer Science & Technology, Vol. I: Fundamentals and Methods” by J. P. Fouassier, J. F. Rabek, Elsevier Applied Science, London and New York, 1993, chapter 5, pages 237 to 240. Generally speaking these are acrylate- or methacrylate-containing compounds which are liquid at room temperature and hence are able to lower the overall viscosity of the formulation. Examples of such products are more particularly isobornyl acrylate, hydroxypropyl methacrylate, trimethylolpropane formal monoacrylate, tetrahydrofurfuryl acrylate, phenoxyethyl acrylate, trimethylolpropane triacrylate, dipropylene glycol diacrylate, tripropylene glycol diacrylate, hexanediol diacrylate, pentaerythritol tetraacrylate, lauryl acrylate, and propoxylated or ethoxylated variants of these reactive diluents, and/or urethanized reactive diluents such as EBECRYL 1039 (Cytec) and others. Also suitable are other liquid components capable of reacting under conditions of free-radical polymerization with, for example, vinyl ether or allyl ether. The amount of D) in the formulation is 5% to 90% by weight, preferably 10% to 70% by weight.
The formulations of the invention may likewise include photoinitiators E). Suitable photoinitiators and their preparation are described in, for example, “Radiation Curing in Polymer Science & Technology, Vol. II: Photoinitiating Systems” by J. P. Fouassier, J. F. Rabek, Elsevier Applied Science, London and New York, 1993. Frequently they are α-hydroxy ketones or derivatives thereof. If present, the photoinitiators can be included in amounts from 0.2% to 10% by weight.
Suitable pigments F) for radiation-curable formulations of the present invention are described in, for example, “Radiation Curing in Polymer Science & Technology, Vol. IV: Practical Aspects and Application” by J. P. Fouassier, J. F. Rabek, Elsevier Applied Science, London and New York, 1993, chapter 5, pages 87 to 105, and can be included in amounts from 1% to 40% by weight. Examples of anti-corrosion pigments are found, for example, in Pigment+Füllstoff Tabellen, O. Lückert, Vincentz Verlag Hanover, 6th edition 2002. Examples include the following: SHIELDEX C 303 (Grace Davison) and HALOX Coil X 100, HALOX Coil X 200 and HALOX CW 491 (Erbslöh), HEUCOPHOS SAPP or else ZPA (Heubach), K-White TC 720 (Tayca) and HOMBICOR (Sachtleben). Of course, simple inorganic salts such as zinc phosphate, for example, are also suitable.
Other adjuvants F) for radiation-curable formulations are available in various compositions and for diverse purposes, examples being flow control agents, matting agents, degassing agents, etc.
Some of them are described in the brochure “SELECTED DEGUSSA PRODUCTS FOR RADIATION CURING AND PRINTING INKS”, published by Tego Coating & Ink Additives, Essen, 2003. The amount of such additives varies from 0.01% to 5% by weight, if present.
The present invention further provides for the use of radiation-curable formulations of the invention as a primer, intercoat, topcoat or clearcoat material and/or in coatings. More particular preference is given to the use of a radiation-curable formulation composed of
The radiation-curable formulation may be applied by techniques that are known within coatings technology, such as knife coating, rolling, spraying or injecting, for example.
The most suitable metallic substrate is steel, optionally pretreated, but suitability as metallic substrate is also possessed by aluminium and other metals or alloys that are given a coating on grounds of corrosion control.
Curing is accomplished in the presence of photoinitiators under UV light or in the absence of photoinitiators under electron beams. The properties of the cured coating materials are largely independent of the curing method.
UV curing and UV lamps are described in, for example, “Radiation Curing in Polymer Science & Technology, Vol. I: Fundamentals and Methods” by J. P. Fouassier, J. F. Rabek, Elsevier Applied Science, London and New York, 1993, chapter 8, pages 453 to 503.
Likewise provided by the invention is the use of a radiation-curable formulation of the invention for producing coatings by the coil coating process, it being possible for the preferential forms described above, as well, to be employed for this subject-matter of the present invention.
The present invention further provides coatings containing or based on radiation-curable formulations according to the present invention. In this context the present invention also and more particularly embraces the cured coatings containing or based on radiation-curable formulations.
The coating of the invention can be used either alone or else as one coat of a multi-coat system. It may be applied, for example, as a primer, as an intercoat or as a topcoat or clearcoat. The coats above or below the coating of the invention may be cured either conventionally, thermally, or else, alternatively, by means of radiation.
Even without further remarks it is assumed that a person skilled in the art will be able to utilize the above description to its widest extent. Consequently the preferred embodiments and examples are to be interpreted merely as a descriptive disclosure which in no way has any limiting effect whatsoever.
The present invention is elucidated below with reference to examples. Alternative embodiments of the present invention are obtainable analogously.
Preparation of a Hydrolysed Organosilane (Dynasylan Glymo)
10 g of Dynasylan GLYMO are admixed with 1.14 g of water (1.5 mol/mol Si) and 0.2 g of boric acid and the mixture is stirred at 70° C. for two hours. Subsequently, at 1 mbar and 70° C., the hydrolysis alcohol produced is removed under reduced pressure. The product is a colorless oligomer which is stable on storage for at least three months.
General Preparation Instructions for the Formulation and Curing of UV Coating Materials
All of the constituents of the formulation are combined and stirred for 20 minutes, using a magnetic stirrer.
The operative formulation is applied by knife coating to steel panels (Bonder panels 1303) and subsequently cured under a UV lamp (3 m/min, Minicure, mercury vapour lamp, 80 W/cm, Technigraf).
All figures in % by weight are based on the total weight of the formulation.
All coatings have sufficient flexibility (Erichsen cupping >5 mm). Only the inventive formulation exhibits sufficient corrosion control (scribe creep <5 cm) after 240 h of salt spray testing (DIN 53167).
| Number | Date | Country | Kind |
|---|---|---|---|
| 10 2007 040 246 | Aug 2007 | DE | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/EP2008/056865 | 6/4/2008 | WO | 00 | 2/24/2010 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2009/027124 | 3/5/2009 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 4026826 | Yoshida et al. | May 1977 | A |
| 4378250 | Treadway et al. | Mar 1983 | A |
| 5221560 | Perkins et al. | Jun 1993 | A |
| 5306856 | Streck et al. | Apr 1994 | A |
| 5591818 | Standke et al. | Jan 1997 | A |
| 5629358 | Nagahata et al. | May 1997 | A |
| 5744675 | Fiolitakis et al. | Apr 1998 | A |
| 5885341 | Standke et al. | Mar 1999 | A |
| 5907000 | Treadway | May 1999 | A |
| 5932757 | Standke et al. | Aug 1999 | A |
| 5959778 | Shimonura et al. | Sep 1999 | A |
| 6133466 | Edelmann et al. | Oct 2000 | A |
| 6239194 | Standke et al. | May 2001 | B1 |
| 6361871 | Jenkner et al. | Mar 2002 | B1 |
| 6395858 | Mack et al. | May 2002 | B1 |
| 6403228 | Mack et al. | Jun 2002 | B1 |
| 6500883 | Mack et al. | Dec 2002 | B1 |
| 6528585 | Standke et al. | Mar 2003 | B1 |
| 6641870 | Bartkowiak et al. | Nov 2003 | B2 |
| 6663683 | Lortz et al. | Dec 2003 | B2 |
| 6676719 | Lortz et al. | Jan 2004 | B2 |
| 6689468 | Edelmann et al. | Feb 2004 | B2 |
| 6695904 | Burger et al. | Feb 2004 | B2 |
| 6699586 | Edelmann et al. | Mar 2004 | B2 |
| 6747070 | Wenning et al. | Jun 2004 | B2 |
| 6767377 | Schumacher et al. | Jul 2004 | B2 |
| 6773697 | Hemme et al. | Aug 2004 | B2 |
| 6773814 | Schumacher et al. | Aug 2004 | B2 |
| 6808769 | Batz-Sohn et al. | Oct 2004 | B2 |
| 6825240 | Wenning et al. | Nov 2004 | B2 |
| 6830816 | Mehnert et al. | Dec 2004 | B2 |
| 6841197 | Standke et al. | Jan 2005 | B2 |
| 6855792 | Speier et al. | Feb 2005 | B2 |
| 6861465 | Wenning et al. | Mar 2005 | B2 |
| 6864323 | Schlosser et al. | Mar 2005 | B2 |
| 6905632 | Lortz et al. | Jun 2005 | B2 |
| 6924385 | Lettmann et al. | Aug 2005 | B2 |
| 6946537 | Krafczyk et al. | Sep 2005 | B2 |
| 6960620 | Wenning et al. | Nov 2005 | B2 |
| 6991190 | Lortz et al. | Jan 2006 | B2 |
| 7015270 | Scharfe et al. | Mar 2006 | B2 |
| 7026398 | Monkiewicz et al. | Apr 2006 | B2 |
| 7083769 | Moerters et al. | Aug 2006 | B2 |
| 7244302 | Schumacher et al. | Jul 2007 | B2 |
| 7255735 | Meyer et al. | Aug 2007 | B2 |
| 7374787 | Lortz et al. | May 2008 | B2 |
| 7399487 | Batz-Sohn et al. | Jul 2008 | B2 |
| 7423165 | Korth et al. | Sep 2008 | B2 |
| 7470423 | Lortz et al. | Dec 2008 | B2 |
| 7514482 | Treadway | Apr 2009 | B2 |
| 7538142 | Lortz et al. | May 2009 | B2 |
| 7572854 | Schneider et al. | Aug 2009 | B2 |
| 7615577 | Lortz et al. | Nov 2009 | B2 |
| 7625975 | Barfurth et al. | Dec 2009 | B2 |
| 7645335 | Lortz et al. | Jan 2010 | B2 |
| 7749322 | Schumacher et al. | Jul 2010 | B2 |
| 7780777 | Perlet et al. | Aug 2010 | B2 |
| 7781520 | Standke et al. | Aug 2010 | B2 |
| 7815936 | Hasenzahl et al. | Oct 2010 | B2 |
| 7834073 | Standke et al. | Nov 2010 | B2 |
| 7976719 | Batz-Sohn et al. | Jul 2011 | B2 |
| 8012367 | Hasenzahl et al. | Sep 2011 | B2 |
| 8039110 | Jenkner et al. | Oct 2011 | B2 |
| 20020016418 | Maruyama et al. | Feb 2002 | A1 |
| 20020098243 | Edelmann et al. | Jul 2002 | A1 |
| 20020127415 | Standke et al. | Sep 2002 | A1 |
| 20020197311 | Hasenzahl et al. | Dec 2002 | A1 |
| 20030018155 | Krafczyk et al. | Jan 2003 | A1 |
| 20030108580 | Hasenzahl et al. | Jun 2003 | A1 |
| 20030134969 | Schlosser et al. | Jul 2003 | A1 |
| 20030228271 | Batz-Sohn et al. | Dec 2003 | A1 |
| 20040240062 | Lortz et al. | Dec 2004 | A1 |
| 20050169861 | Lortz et al. | Aug 2005 | A1 |
| 20050265934 | Schumacher et al. | Dec 2005 | A1 |
| 20060063002 | Edelmann et al. | Mar 2006 | A1 |
| 20060104881 | Lortz et al. | May 2006 | A1 |
| 20060159635 | Meyer et al. | Jul 2006 | A1 |
| 20060159636 | Meyer et al. | Jul 2006 | A1 |
| 20060159637 | Meyer et al. | Jul 2006 | A1 |
| 20060163533 | Batz-Sohn et al. | Jul 2006 | A1 |
| 20060229210 | Neugebauer et al. | Oct 2006 | A1 |
| 20060292192 | Hasenzahl et al. | Dec 2006 | A1 |
| 20070099004 | Edelmann et al. | May 2007 | A1 |
| 20070110906 | Edelmann et al. | May 2007 | A1 |
| 20070114491 | Shi et al. | May 2007 | A1 |
| 20070231280 | Schumacher et al. | Oct 2007 | A1 |
| 20070297998 | Meyer et al. | Dec 2007 | A1 |
| 20080027161 | Schlosser et al. | Jan 2008 | A1 |
| 20080058489 | Edelmann et al. | Mar 2008 | A1 |
| 20080095724 | Hasenzahl et al. | Apr 2008 | A1 |
| 20080187673 | Standke et al. | Aug 2008 | A1 |
| 20080200577 | Spyrou et al. | Aug 2008 | A1 |
| 20080206572 | Edelmann et al. | Aug 2008 | A1 |
| 20080213325 | Schumacher et al. | Sep 2008 | A1 |
| 20080221318 | Edelmann et al. | Sep 2008 | A1 |
| 20080249237 | Hager et al. | Oct 2008 | A1 |
| 20080264299 | Lortz et al. | Oct 2008 | A1 |
| 20090005518 | Just et al. | Jan 2009 | A1 |
| 20090007818 | Militz et al. | Jan 2009 | A1 |
| 20090022898 | Standke et al. | Jan 2009 | A1 |
| 20090030162 | Mueh et al. | Jan 2009 | A1 |
| 20090047225 | Hasenzahl et al. | Feb 2009 | A1 |
| 20090069464 | Standke | Mar 2009 | A1 |
| 20090131694 | Schumacher et al. | May 2009 | A1 |
| 20090186053 | Meyer et al. | Jul 2009 | A1 |
| 20090261309 | Lortz et al. | Oct 2009 | A1 |
| 20100117021 | Batz-Sohn et al. | May 2010 | A1 |
| 20100119851 | Giessler-Blank et al. | May 2010 | A1 |
| 20100159144 | Standke et al. | Jun 2010 | A1 |
| 20100191001 | Wassmer et al. | Jul 2010 | A1 |
| 20100209339 | Schumacher et al. | Aug 2010 | A1 |
| 20100209719 | Borup et al. | Aug 2010 | A1 |
| 20100233392 | Batz-Sohn et al. | Sep 2010 | A1 |
| 20100308287 | Lortz et al. | Dec 2010 | A1 |
| 20110034584 | Albert et al. | Feb 2011 | A1 |
| 20110045723 | Nowak et al. | Feb 2011 | A1 |
| 20110071256 | Nowak et al. | Mar 2011 | A1 |
| 20110143147 | Edelmann et al. | Jun 2011 | A1 |
| 20110259240 | Jenkner et al. | Oct 2011 | A1 |
| 20110268899 | Albert et al. | Nov 2011 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 978 525 | Feb 2000 | EP |
| 1 693 690 | Aug 2006 | EP |
| WO 2009021766 | Feb 2009 | WO |
| Entry |
|---|
| (6-Cumene)(5-cyclopentadienyl)iron(II)hexafluorophosphate; Irgacure 261 chemical listing from ChemBlink.com. [online]. [Retrieved online on Feb. 23, 2012]. Retrieved from internet <URLhttp://www.chemblink.com/products/32760-80-8.htm>.:. |
| U.S. Appl. No. 08/124,955, filed Sep. 21, 1993, Standke, et al. |
| U.S. Appl. No. 10/112,045, filed Apr. 1, 2002, Mehnert, et al. |
| U.S. Appl. No. 12/992,684, filed Mar. 4, 2011, Nowak, et al. |
| U.S. Appl. No. 13/058,290, filed Feb. 9, 2011, Weissenbach, et al. |
| U.S. Appl. No. 13/059,546, filed Feb. 17, 2011, Weissenbach, et al. |
| U.S. Appl. No. 13/062,225, Mar. 4, 2011, Weissenbach, et al. |
| U.S. Appl. No. 61/093,219, filed Aug. 29, 2008, Simoes. |
| U.S. Appl. No. 13/061,451, filed Feb. 28, 2011, Weissenbach, et al. |
| U.S. Appl. No. 13/011,115, filed Jan. 21, 2011, Ruf, et al. |
| U.S. Appl. No. 12/440,927, filed Mar. 12, 2009, Spyrou, et al. |
| U.S. Appl. No. 12/673,390, filed Feb. 12, 2010, Wassmer, et al. |
| U.S. Appl. No. 12/673,289, filed Feb. 12, 2010, Koschabek, et al. |
| U.S. Appl. No. 12/520,873, filed Jun. 23, 2009, Spyrou, et al. |
| U.S. Appl. No. 12/161,112, filed Jul. 16, 2008, Standke, et al. |
| U.S. Appl. No. 12/933,028, filed Sep. 16, 2010, Spyrou. |
| U.S. Appl. No. 13/257,488, filed Oct. 21, 2011, Standke, et al. |
| U.S. Appl. No. 13/256,557, filed Sep. 14, 2011, Scharfe, et al. |
| Number | Date | Country | |
|---|---|---|---|
| 20110144226 A1 | Jun 2011 | US |